Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: Bob L who wrote (2679)	10/25/1998 7:18:00 PM
From: Maurice Winn	Read Replies (1) \| Respond to of 3702

Thanks Bob, "True, the radiation should kill the nasty cells, but the molecule just doesn't stick to the aggressive grades well." Is it the monoclonal antibody molecule not sticking to the cancer cell or the I131 falling off the cancer cell and monoclonal antibody combination even before the attachment to the cancer cell occurs? Maybe they just need better glue between the I131 and the molecule. Whatever, it puts them at a time to market disadvantage. "Back to the drawing board" is always a pain. Maurice PS: *OT* On the personal stuff, it amazes me how much personal invective there is even in the sacred halls of SI civilisation where usually there are only harps and dulcet notes of harmony as the mysteries of the universe and different points of views and values are extricated from the fractalized universe and delivered happily into our consciousness the better that we may wend our tortuous way through an infinitely complex life on the road to nirvana. Meanwhile, over in the mad village of TCLN Yahoo! they are all happily chatting about their trip to Aruba and making SI look like an enclave in Kosovo, hamlet in Rwanda or even the main vestibule of The Capitol after a dropout from the mental health practises in the USA comes visiting.